92 results about "Mucosal disease" patented technology

Stable, viscous, mucoadhesive aqueous compositions which are useful for the prevention and treatment of ulcerative, inflammatory, and/or erosive disorders of mucous membranes and/or the delivery of pharmaceutically active compounds to mucosal surfaces for topical treatment or transfer to the systemic circulation.

PCT No. PCT/CA96/00488 Sec. 371 Date Dec. 24, 1997 Sec. 102(e) Date Dec. 24, 1997 PCT Filed Jul. 18, 1996 PCT Pub. No. WO97/03699 PCT Pub. Date Feb. 6, 1997The use of an effective amount of a composition comprising an N.S.A.I.D. and a form of hyaluronic acid selected from hyaluronic acid, pharmaceutically acceptable salts thereof, fragments thereof and/or subunits thereof for mucous membrane trauma, disease, and/or pain relief.

Stable, viscous, mucoadhesive aqueous compositions which are useful for the prevention and treatment of ulcerative, inflammatory, and/or erosive disorders of mucous membranes, especially mucositis.

The invention relates to an antibacterial composition based on a natural plant raw material and an application of the antibacterial composition, especially prevention and treatment of skin and mucosal diseases and infection of people and animals. The medicine tolerance problem of an antibiotic is an increasingly serious problem in global attention. The invention aims at providing a safe and effective natural antibacterial composition to avoid the problem of the medicine tolerance of the antibiotic instead of the antibiotic. The natural antibacterial composition provided by the invention has a broad-spectrum efficient sterilization effect, and is effective for gram-positive bacterium, gram-negative bacterium and fungus; candida albicans, staphylococcus aureus and escherichia coli can be completely killed within one minute; and meanwhile, the antibacterial composition has good safety. In addition, the composition also has the efficacy of resisting viruses, inflammation and allergy. The composition can be used for preventing and treating skin and mucosal diseases and infection of people and animals. The problem of the medicine tolerance generated by functional antibiotics is avoided.

The invention provides a medicine for curing an oral mucosal disease. The medicine is prepared by the following raw traditional Chinese medical materials: mint, mulberry leaves, chrysanthemums, roots of straight ladybell, radix scrophulariae, ophiopogon roots, radix rehmanniae recen, angelica, rhizoma anemarrhenae, fiveleaf akebia, lophatherum gracile, atractylodes, Tuckahoe, honeysuckle flowers, scutellaria, trichosanthes roots, gardenia, balloon flowers and liquorice. All components in the invention are used to jointly take the efficacy of nourishing Yin, reducing fever, clearing lung and stomach, dispelling wind, reducing pathogenic fire and enriching the blood to restore normal menstruation. The invention differentially cures the vulvar leukoplakia by traditional Chinese medical science, has ideal curing effect and achieves a curative ratio up to 85 percent so that patients can be cured for 6-10 days.

The present disclosure generally relates to the medical use of compositions comprising a mineral salt and a sulfonic acid for prevention and/or treatment of one or more mucosal diseases, disorders, or conditions or one or more dermal diseases, disorders, or conditions.

Nanoemulsified topical formulation comprising curcumin, tetrahydroxycurcumin (BDMC) and curcuminoid either alone or in combinations in an amount of 0.001% to 50% together with one or more pharmaceutically, nutraceutically or dietically acceptable excipient(s) or inactive ingredients, useful for the treatment of inflammation, various skin and oral disorders, mucosal disorders and other diseases associated or related thereof.

The invention relates to a plasma mucocutaneous disease therapeutic apparatus. The apparatus comprises a master control unit, a drive power supply, a miniature air pump, a plasma generation unit and a therapeutic head, wherein the plasma generation unit is provided with an air inlet and an air outlet; the master control unit is respectively connected with the drive power supply and the miniature air pump; the drive power supply is connected with the plasma generation unit; the air pump is connected with the air inlet of the plasma generation unit; and the therapeutic head is connected with the air outlet of the plasma generation unit. The plasma mucocutaneous disease therapeutic apparatus solves the technical problems of high cost, large size and complex operation of a conventional plasma mucocutaneous disease therapeutic apparatus, has the advantages of smart size, simpleness in operation and convenience for carrying, and is suitable for home self-treatment of patients.

The present invention provides therapeutic compositions comprising extracts of the plant species Echinacea purpurea and Sambucus nigra and the extract(s) of at least one further plant selected from the group consisting of Hypericum perforatum, Commiphora molmol and Centella asiatica. The compositions of the invention are of particular utility in the management of inflammatory mucosal diseases of both viral and non-viral origin.

The invention discloses a mucosal disease treatment system. The mucosal disease treatment system comprises a biological adhesive, a biological medical material, and medical instruments, wherein the biological adhesive comprises the following components: a component a, namely a functionalized star polymer or/and a functionalized comb polymer, and a component b, namely functional polysaccharide; anactive group of the component a and an active group of the component b can chemically react to form a new chemical bond; the biomedical materials, which are selected according to different mucosal diseases, are mixed in the component a of the biological adhesive, or in the component b of the biological adhesive, or partially mixed in the component a of the biological adhesive and partially mixed in the component b of the biological adhesive. When the system is in use, one of the components a and b is covered on a mucous membrane to be treated with the aid of a corresponding medical instrument,and the other component is covered on the previous component; the biological adhesive is firmly adhered to the mucous membrane and seals and repairs the mucous membrane; and the biological medical material is continuously released into adhesive tissues, thereby treating mucosal diseases.

The invention relates to an externally-applied medicine for treating skin and mucosa disease caused by human papilloma virus, which is prepared from Chinese medicinal herbs including cnidium fruit, dysosmapleiantha woods, brucea fruit, poria cocos, cordate houttuynia, flavescent sophora root and wasp's nest. The preferred dosage form of the preparation is soft electuary.

A computerized-method for a mucosal assessment of a mucosal disease in a Gastrointestinal Tract (GIT) of a subject, including receiving a stream of images of at least a portion of the GIT, parsing the stream into a plurality of segments, wherein each segment corresponds to a region of the at least portion of the GIT, obtaining a set of values for each segment, wherein the set of values refers to the pathological involvement of the segment in the mucosal disease and to severity of mucosal manifestation of the mucosal disease in the segment, and based on said set of values for each segment, generating a representation indicating the location and severity of the mucosal manifestation of the mucosal disease in the entirety of the at least portion of the subject's GIT, thereby allowing to assess the condition of the mucosal disease in the at least portion of the GIT.

The invention discloses a composition for preventing and treating mucous membrane diseases with staphylococcus aureus, escherichia coli and candida albicans as pathogenic bacteria and a preparation method thereof. The composition is characterized by being prepared from the following components in percentage by mass: 0.001-35 percent of an antimicrobial agent, 0-10.0 percent of an analgesic, 0.001-20.0 percent of a bio-adhesive, 0-30.0 percent of a humectant, 0-5.0 percent of a pH regulator, 0-8.0 percent of a flavoring agent, 0-5.0 percent of an emulsifier, 0-8.0 percent of an auxiliary antimicrobial agent and the balance of pure water, totally 100 percent. The components in the composition can be well combined to achieve functions of inhibiting bacteria, isolating, relieving pain and moistening, and the effects of isolating microbial infection, preventing secondary infection and accelerating wound healing can be achieved. The composition is especially suitable for preventing and treating mucous membrane diseases in the oral cavity, nasal cavity, gastrointestinal tracts, respiratory tracts, vagina, urinary bladder, genitals, epidermis and other positions.

Proguanil has been found to have rapid and effective killing activity against a variety of disease-causing micro organisms. For example, when applied topically, proguanil is particularly effective against Propionibacterium acnes, a bacteria that causes acne; Corynebacterium minutissimum, a bacteria that causes erythrasma, Gardnerella vaginalis, a bacteria that causes vaginosis; Trichomonas vaginalis, a protozoan that causes trichomoniasis and C. albicans, a fungus (a form of yeast).

The invention relates to the technical field of daily consumer goods for killing malignant bacteria, viruses and funguses in oral cavity and throat, cleaning the oral cavity and preventing and treating oral diseases, and in particular relates to nano-silver mouth wash for preventing and treating oral diseases and a preparation method thereof. The mouth wash is characterized by comprising 0.1ppm-1000ppm nano silver and the following components in percentage by weight: 0.01-5% of a hemostatic, 0.01-5% of a topical anaesthetic, 0.01-10% of a bacteriostatic agent, 0.1-25% of a dispersant, 0.1-25% of a thickener, 0.1-15% of a wetting agent, 0.1-10% of an algefacient, 0.1-35% of an adhesive agent, 0.01-5% of a corrigent and 0.01-5% of a colorant. The principle is as follows: silver particles with diameter of 10-50 nanometers can be absorbed to cytomembranes of harmful microorganisms to damage protein capsids and DNA (Deoxyribonucleic Acid) molecules of the harmful microorganisms to lead to death of the harmful microorganisms by interfering metabolism of the harmful microorganisms, so that the nano-silver mouth wash has broad spectrum sterilizing and bacteriostatic effect, is durable and effective in effect, free from toxic and side effects as well as drug resistance, safe and reliable, convenient to use, simple in production and preparation, and has very good preventing and treating effect to periodontal disease, acute and chronic aryngitis and oral mucosal diseases.

The invention generally relates to compositions comprising a soluble chitosan derivative and an H2 receptor antagonist, and the use of the compositions for treating skin or mucosal diseases, such as inflammatory diseases or infectious disease.

The invention discloses a deer-derived bovine viral diarrhea inactivated vaccine and a preparation method thereof, relates to the technical field of vaccines, and fills the blank of a vaccine specialfor viral diarrhea/mucosal diseases of sika deer. The deer-derived bovine viral diarrhea inactivated vaccine JL05 is preserved in the CGMCC on January 11, 2018, with a collection number of CGMCC No.15283. The deer-derived BVDVJL05 virus is subjected to passage by using MDBK cells and then is subjected to plaque cloning to purify the virus; detection shows that the content of the deer-derived BVDVJL05 virus is 107.2 TCID50/ml or more, and no germ, mold, mycoplasma or exogenous virus pollution is caused; the deer-derived BVDV JL05 virus meets a virus requirement for vaccine preparation. The virus is inactivated by BEI and then is mixed and emulsified with a 206 adjuvant to prepare the vaccine; safety and potency inspection shows that the vaccine is safe to the sika deer, and the challenge protection rate can be up to 100 percent.